December 19, 2017 / 12:14 PM / 10 months ago

BRIEF-Critical Outcome Technologies Announces Data From Phase 1 Dose Escalation Portion Of COTI-2 Trial In Gynecological Malignancies

Dec 19 (Reuters) - Critical Outcome Technologies Inc :

* CRITICAL OUTCOME TECHNOLOGIES ANNOUNCES PHARMACODYNAMIC DATA AND POSITIVE SIGNALS OF EFFICACY FROM PHASE 1 DOSE ESCALATION PORTION OF COTI-2 TRIAL IN GYNECOLOGICAL MALIGNANCIES

* CRITICAL OUTCOME TECHNOLOGIES- ‍WELL-POSITIONED TO CONTINUE ADVANCING COTI-2 THROUGH CLINICAL DEVELOPMENT, EXPECT TO REPORT ADDITIONAL DATA IN YEAR AHEAD​

* CRITICAL OUTCOME TECHNOLOGIES INC - ‍HAVE ESTABLISHED A RECOMMENDED PHASE 2 DOSE FOR COTI-2 IN OVARIAN CANCER​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below